Description
What Is Iclusig (Ponatinib)?
Iclusig (Ponatinib) is a prescription medicine developed by Takeda Pharmaceuticals, designed to treat specific types of blood cancer such as Chronic Myeloid Leukemia (CML) and Philadelphia chromosome–positive Acute Lymphoblastic Leukemia (Ph+ ALL).
This medication belongs to a class of drugs known as Tyrosine Kinase Inhibitors (TKIs), which work by blocking the activity of enzymes that promote the growth of cancerous cells. Iclusig is particularly effective in patients who have developed resistance or intolerance to previous therapies such as Imatinib, Dasatinib, or Nilotinib, especially in the presence of the T315I mutation.
⚕️ Indications for Use
Treatment of adults with chronic, accelerated, or blast phase CML.
Treatment of adults with Ph+ ALL who are resistant to or intolerant of other TKIs.
Used when genetic testing shows T315I mutation, resistant to first-line therapies.
Helps reduce the proliferation of abnormal white blood cells in bone marrow.
Dosage and Administration
The usual starting dose is 45 mg once daily, taken orally.
Tablets can be taken with or without food.
Swallow the tablet whole; do not crush or chew it.
Dosage may be adjusted based on the patient’s response or side effects.
Regular monitoring of blood counts and liver function is required throughout therapy.
⚠️ Warnings and Precautions
Iclusig may cause blood clots, arterial occlusion, or stroke.
Monitor heart and liver function regularly during treatment.
Avoid using grapefruit juice, as it can increase drug concentration in the blood.
Not recommended for use during pregnancy or breastfeeding.
Patients with a history of cardiac disease or hypertension should consult their doctor before starting therapy.
Possible Side Effects
Headache, dizziness, or fatigue
Nausea, vomiting, or stomach discomfort
Elevated blood pressure
Liver toxicity or abnormal liver enzymes
Fluid retention or swelling of the hands and feet
Chest pain or irregular heartbeat
⚠️ Seek medical attention immediately if you experience sudden chest pain, shortness of breath, yellowing of the skin/eyes, or signs of stroke.
⭐ User Reviews
⭐⭐⭐⭐⭐
“Iclusig changed my life. After failing other leukemia treatments, this one gave me real progress with manageable side effects.”
⭐⭐⭐⭐
“Effective medication, but requires regular monitoring and lab tests. Definitely worth it under close supervision.”
Internal Links
❓ Frequently Asked Questions (FAQs)
1. What is Iclusig used for?
It is used to treat chronic myeloid leukemia (CML) and Ph+ ALL that are resistant to other treatments.
2. Who manufactures Iclusig?
Iclusig is produced by Takeda Pharmaceuticals, a leading Japanese pharmaceutical company.
3. How does Iclusig work?
It blocks tyrosine kinase enzymes, stopping cancer cells from multiplying.
4. What is the typical dosage?
The usual starting dose is 45 mg once daily, adjusted as needed.
5. Can I take Iclusig with food?
Yes, it can be taken with or without food.
6. Does Iclusig have severe side effects?
Possible severe effects include blood clots, liver toxicity, and hypertension.
7. Can I take Iclusig during pregnancy?
No, it is not recommended during pregnancy or breastfeeding.
8. Does it interact with other medicines?
Yes, tell your doctor about all medications you take to avoid interactions.
9. How long does treatment last?
Duration varies depending on the patient’s response and condition.
10. Is Iclusig available in Egypt?
Yes, Iclusig 15 mg tablets are available through No Style Like and authorized distributors.
Reviews
There are no reviews yet.